IntegraGen and GoPath Laboratories Sign Licensing Agreement for the Commercialization of Mir-31-3P Test in North America
January 09, 2018 at 12:00 pm EST
IntegraGen and GoPath Laboratories announced the signing of a non-exclusive licensing agreement allowing GoPath to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to physicians in the United States and Canada. The test will complement GoPath’s specialized molecular diagnostic testing portfolio for cancer and enable clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.